甲状腺血管肉瘤的诊断和治疗进展  

Advances in diagnosis and treatment of thyroid angiosarcoma

作　　者：张炳洲 张波林 张维[2] 姜霞[1] 王松[3] 田延锋[1] 赵增仁[1] Zhang Bingzhou;Zhang Bolin;Zhang Wei;Jiang Xia;Wang Song;Tian Yanfeng;Zhao Zengren(Department of Glandular Surgery,The First Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei,China;Department of Thyroid and Breast Surgery,Cangzhou Central Hospital,Cangzhou 061000,Hebei,China;Department of Thyroid Surgery,Affiliated Hospital of Chengde Medical University,Chengde 067000,Hebei,China)

机构地区：[1]河北医科大学第一医院腺体外科,河北石家庄050000 [2]沧州市中心医院甲状腺乳腺外科,河北沧州061000 [3]承德医学院附属医院甲状腺外科,河北承德067000

出　　处：《中国现代手术学杂志》2023年第3期242-247,共6页Chinese Journal of Modern Operative Surgery

基　　金：河北省重点研发计划项目(21372401D)。

摘　　要：甲状腺血管肉瘤是一种罕见的甲状腺恶性肿瘤,发病机制不明,临床表现为迅速增大的无痛性颈部肿物,缺乏特异性影像表现,因其病理特征及免疫组化与甲状腺间变性癌相似而易被误诊,根治性手术切除是其主要治疗手段,术后辅助放疗可以改善患者预后。随着分子生物学的发展,靶向治疗和免疫治疗有了更多的临床报道,丰富了甲状腺血管肉瘤的治疗手段,使部分患者可以从中获益。Thyroid angiosarcoma(TAS)is a rare malignant thyroid gland tumor with unknown pathogenesis.The clinical manifestation is a rapidly enlarging and painless neck mass that lacks specific imaging features.TAS is easy to be misdiagnosed due to its similar pathological characteristics and immunohistochemistry to anaplastic thyroid carcinoma.Radical resection is the primary treatment,and postoperative adjuvant radiotherapy can improve the prognosis of TAS patients.In recent years,with the development of molecular biology,there are more clinical reports of targeted therapy and immunotherapy,which enrich the treatment of TAS and enable some patients to benefit from them.

关 键 词：甲状腺血管肉瘤 甲状腺间变性癌 预后 

分 类 号：R736.1[医药卫生—肿瘤]